David Malcom Rodman - Aug 10, 2023 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role
Chief Medical Officer
Signature
/s/ Adam Levy, Attorney-in-fact
Stock symbol
MLYS
Transactions as of
Aug 10, 2023
Transactions value $
-$2,828,136
Form type
4
Date filed
8/11/2023, 07:11 PM
Previous filing
Mar 21, 2023
Next filing
Nov 7, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MLYS Common Stock Options Exercise $40.3K +74.6K $0.54* 74.6K Aug 10, 2023 Direct
transaction MLYS Common Stock Sale -$982K -74.6K -100% $13.16 0 Aug 10, 2023 Direct F1
transaction MLYS Common Stock Options Exercise $43.7K +80.9K $0.54* 80.9K Aug 11, 2023 Direct
transaction MLYS Common Stock Sale -$1.04M -80.9K -100% $12.81 0 Aug 11, 2023 Direct F2
transaction MLYS Common Stock Options Exercise $82.3K +76.2K $1.08* 76.2K Aug 11, 2023 Direct
transaction MLYS Common Stock Sale -$976K -76.2K -100% $12.81 0 Aug 11, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MLYS Stock Option Options Exercise $0 -74.6K -30.99% $0.00 166K Aug 10, 2023 Common Stock 74.6K $0.54 Direct F3, F4
transaction MLYS Stock Option Options Exercise $0 -80.9K -48.68% $0.00 85.3K Aug 11, 2023 Common Stock 80.9K $0.54 Direct F3, F4
transaction MLYS Stock Option Options Exercise $0 -76.2K -25% $0.00 229K Aug 11, 2023 Common Stock 76.2K $1.08 Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is the weighted-average sales price, sold in multiple transactions at prices ranging from $13.00 to $13.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.
F2 The price reported is the weighted-average sales price, sold in multiple transactions at prices ranging from $12.39 to $13.185, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.
F3 Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023.
F4 The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.
F5 Due to a rounding error, the exercise price for this stock option was originally reported as $1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023.
F6 The stock option vested with respect to 25% of the underlying shares on July 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.